EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics

Harald Hampel iD, Aya Elhage, Min Cho, Liana G Apostolova, James A R Nicoll, Alireza Atri

Brain · 02.11.2023 · 146 (11) · 4414-4424

DOI: 10.1093/brain/awad188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 06.06.2023. Verfasst von Harald Hampel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc., Alzheimer's Disease and Brain Health, Nutley, NJ 07110, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 434-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer’s disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target amyloid-β and have identified MRI signal abnormalities called amyloid-related imaging abnormalities (ARIA) as possible spontaneous or treatment-related adverse events. This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification challenges, pathophysiology, underlying biological mechanism(s) and risk factors/predictors associated with ARIA. We summarize the existing literature and current lines of evidence with ARIA-oedema/effusion (ARIA-E) and ARIA-haemosiderosis/microhaemorrhages (ARIA-H) seen across anti-amyloid clinical trials and therapeutic development. Both forms of ARIA may occur, often early, during anti-amyloid-β monoclonal antibody treatment. Across randomized controlled trials, most ARIA cases were asymptomatic. Symptomatic ARIA-E cases often occurred at higher doses and resolved within 3–4 months or upon treatment cessation. Apolipoprotein E haplotype and treatment dosage are major risk factors for ARIA-E and ARIA-H. Presence of any microhaemorrhage on baseline MRI increases the risk of ARIA. ARIA shares many clinical, biological and pathophysiological features with Alzheimer’s disease and cerebral amyloid angiopathy. There is a great need to conceptually link the evident synergistic interplay associated with such underlying conditions to allow clinicians and researchers to further understand, deliberate and investigate on the combined effects of these multiple pathophysiological processes. Moreover, this review article aims to better assist clinicians in detection (either observed via symptoms or visually on MRI), management based on appropriate use recommendations, and general preparedness and awareness when ARIA are observed as well as researchers in the fundamental understanding of the various antibodies in development and their associated risks of ARIA. To facilitate ARIA detection in clinical trials and clinical practice, we recommend the implementation of standardized MRI protocols and rigorous reporting standards. With the availability of approved amyloid-β therapies in the clinic, standardized and rigorous clinical and radiological monitoring and management protocols are required to effectively detect, monitor, and manage ARIA in real-world clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAntibodies, Monoclonal, HumanizedAmyloid beta-PeptidesBrainAmyloidAmyloidogenic Proteins

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloid-related imaging abnormalitiesanti-amyloid monoclonal antibodiescerebral amyloid angiopathydisease-modifying therapies

Substanzen

Antibodies, Monoclonal, HumanizedAmyloid beta-PeptidesAmyloidAmyloidogenic Proteins

Autor:innen und Institutionen

  • Eisai Inc., Alzheimer's Disease and Brain Health, Nutley, NJ 07110, USA.
  • Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Division of Clinical Neurosciences, Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UK.
  • Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
  • Banner Sun Health Research Institute, Banner Health, Sun City, AZ 85351, USA.

ORCID-Profile: Harald Hampel

Förderung

  • NIA NIH HHS

Zitieren

APA

Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023). Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain, 146(11), 4414-4424. https://doi.org/10.1093/brain/awad188

Vancouver

Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414-4424. doi:10.1093/brain/awad188

BibTeX
@article{Hampel2023,
  author = {Hampel, Harald and Elhage, Aya and Cho, Min and Apostolova, Liana G and Nicoll, James A R and Atri, Alireza},
  title = {Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {11},
  pages = {4414--4424},
  doi = {10.1093/brain/awad188}
}
Kostenlos starten →